Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- MEDICINE105(5) · 2026
- 피인용
- Web of Science 1Scopus 1
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 1.4
- ISSN
- 0025-7974
저자
- Yang, Chia-Jui제1저자Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan
- Kim, Yeon-SookChungnam Natl Univ, Sch Med, Dept Internal Med, Div Infect Dis, Daejeon, South Korea
- Choi, Jun YongYonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea
- Choy, Chiaw YeeNatl Ctr Infect Dis, Dept Infect Dis, Singapore, Singapore
- Lu, Po-LiangKaohsiung Med Univ, Coll Med, Sch Postbaccalaureate Med, Kaohsiung, Taiwan
- Tsai, Hung-ChinNatl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
- Ryu, JulieGlobal Med Affairs, Gilead Sci, Foster City, CA USA
- Harrison, RebeccaIQVIA, Real World Solut, London, England
- Chang, JackGilead Sci, Med Affairs, Taipei, Taiwan
- Mo, BillyGilead Sci, Med Affairs, Taipei, Taiwan
- 이선희Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea
- Hung, Chien-Ching교신저자Natl Taiwan Univ Hosp, Yunlin Branch, Dept Internal Med, Yunlin, Taiwan
초록
BICtegravir Single Tablet Regimen is a multiregional, observational cohort study assessing the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV. We present 24-month data for the BICtegravir Single Tablet Regimen Asia cohort. Between December 2020 and March 2024, prospective and retrospective data were collected from TN and TE people with HIV receiving B/F/TAF in routine clinical care in the Republic of Korea, Singapore, and Taiwan. Endpoints at month 24 included effectiveness (HIV-1 RNA <50 copies/mL; missing = excluded and discontinuation = failure analyses), immunological endpoints (CD4 cell count and CD4/CD8 ratio), persistence, safety, and patient-reported outcomes (prospective cohort). Overall, 334 participants (252 prospective, 82 retrospective; 66 TN, 268 TE) were included in the analysis population. Most were male (97% TN, 93% TE) with ≥1 comorbidity (56% TN, 67% TE). At month 24, HIV-1 RNA was <50 copies/mL in 91% (50/55) of TN and 97% (225/331) of TE participants (missing = excluded analysis). Median (quartile [Q]1, Q3) CD4 count increased by +260 (155, 386; P < .001) cells/μL in TN and +40 (−65, 150; P = .008) cells/μL in TE participants. Median (Q1, Q3) CD4/CD8 ratio increased by +0.38 (0.21, 0.48; P < .001) in TN and +0.08 (0.00, 0.19; P < .001) in TE participants. Patient-reported outcomes indicated an improvement in mental health and a decrease in the number of bothersome symptoms in TN participants. Persistence at month 24 was high, with 98% (60/61) of TN and 97% (251/260) of TE participants remaining on B/F/TAF. Drug-related adverse events occurred in 9% (6/66) of TN and 8% (22/268) of TE participants, leading to B/F/TAF discontinuation in <1% (3/334) of participants, all of whom were TE. B/F/TAF demonstrated high levels of effectiveness, persistence, and tolerability over 24 months in people with HIV in Asia.
키워드
antiretroviral therapyAsiaB/F/TAFbictegravirreal-world evidence
식별자
- Scopus EID
- 2-s2.0-105029338774
- WoS UID
- 001680486200039



로그인
연구물 목록으로